Emergence of HBV resistance to lamivudine (3TC) in HIV/HBV co-infected patients in The Gambia, West Africa

BMC Research Notes

Table 2 Patterns of mutation found in patients who developed YMDD 3TC resistant mutants

Patient ID	3TC Mutations			Time after initiation of LMV therapy (months)
Patient 6	M204V	L180M		25
Patient 12	M204V	L180M	V173L*	16
Patient 13	M204V	L180M		36

Times given for when mutation occurred correspond to the first sample given during therapy in which resistance mutations were detected.
*V173L mutation occurred after 23 months from initiation of therapy.

ISSN: 1756-0500